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Abstract: Retinitis pigmentosa (RP) is a group of inherited disorders affecting 1 in 3000-7000 people and characterized 
by abnormalities of the photoreceptors (rods and cones) or the retinal pigment epithelium of the retina which lead to 
progressive visual loss. RP can be inherited in an autosomal dominant, autosomal recessive or X-linked manner. While 
usually limited to the eye, RP may also occur as part of a syndrome as in the Usher syndrome and Bardet-Biedl syndrome. 
Over 40 genes have been associated with RP so far, with the majority of them expressed in either the photoreceptors or 
the retinal pigment epithelium. The tremendous heterogeneity of the disease makes the genetics of RP complicated, thus 
rendering genotype-phenotype correlations not fully applicable yet. In addition to the multiplicity of mutations, in fact, 
different mutations in the same gene may cause different diseases. We will here review which genes are involved in the 
genesis of RP and how mutations can lead to retinal degeneration. In the future, a more thorough analysis of genetic and 
clinical data together with a better understanding of the genotype-phenotype correlation might allow to reveal important 
information with respect to the likelihood of disease development and choices of therapy. 
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1. WHAT IS RETINITIS PIGMENTOSA? 
  Retinitis pigmentosa (RP) is a class of diseases involving 
progressive degeneration of the retina, typically starting in 
the mid-periphery and advancing toward the macula and 
fovea. Typical symptoms include night blindness followed 
by decreasing visual fields, leading to tunnel vision and 
eventually legal blindness or, in many cases, complete 
blindness [1]. On the cellular level, this correlates with a 
predominantly affected rod photoreceptor system. In later 
stages, the disease may further affect the cone photoreceptor 
eventually causing complete blindness. The diseased 
photoreceptors undergo apoptosis [2], which is reflected in 
reduced outer nuclear layer thickness within the retina, as 
well as in lesions and/or retinal pigment deposits in the 
fundus. Patients may lose a significant portion of their 
photoreceptors before experiencing loss of visual acuity. 
Clinical hallmarks are (i) an abnormal fundus with bone-
spicule deposits and attenuated retinal vessels, (ii) abnormal, 
diminished or absent a- and b-waves in the electroretinogram 
(ERG) and (iii) reduced visual field. Symptoms typically 
start in the early teenage years and severe visual impairment 
occurs by ages 40 to 50 years (reviewed in [3]). A 
multicenter study evaluating visual acuity (VA) data from 
999 patients (age 45 years or older) with different genetic 
subtypes of RP found that 52% had a VA of 20/40 or better, 
69% of 20/70 or better, 25% of 20/200 or worse and 0,5%  
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had no light perception in both eyes [4]. There are also early-
onset forms of RP (the earliest is indistinguishable from 
Leber congenital amaurosis) and other late-onset or even 
non-penetrant forms. 
  RP, broadly defined to include simple, syndromic and 
systemic disease, has a worldwide prevalence of 1:3000 to 
1:7000 people. Usually, no sex predilection exists. However, 
as X-linked RP is expressed only in males, statistically men 
may be affected slightly more than women. RP shows no 
ethnic specificity, but RP caused by mutations in particular 
genes may be more frequent in certain isolated or 
consanguineous populations (such as the USH3 gene 
associated with type III Usher syndrome, normally rare, but 
more common among Finns and Ashkenazi Jews). 
  The genetics of RP is varied. After the first report 
describing a linkage of an RP locus to a DNA marker on 
human chromosome X in 1984 [5], over 40 genes have been 
associated with RP (Table 1). Non-syndromic or “simple” 
cases may be inherited as an autosomal dominant (20-25%); 
Fig. (1)), autosomal recessive (15-20%; Fig. (2)), X-linked 
recessive (10-15%; Fig. (3)), or sporadic/simplex traits 
(30%), and 5% may be early-onset and grouped as part of 
Leber congenital amaurosis (LCA). Rarer forms also exist, 
such as X-linked dominant, mitochondrial, and digenic (due 
to mutations in two different genes). While RP is a disease 
usually limited to the eye, there are syndromic forms 
involving multiple organs and pleiotropic effects as well as 
systemic forms wherein the retinal disease is secondary to a 
system-wide pathology. The most frequent forms of 
syndromic RP are Usher syndrome (RP usually develops by 
the early teenage years) and Bardet-Biedl syndrome. Retinitis Pigmentosa  Current Genomics, 2011, Vol. 12, No. 4    239 
Table 1.  Summary of Genes Associated with RP (Adapted from http://www.sph.uth.tmc.edu/retnet/) 
Disease  Total No. of Genes and Loci  No. of Identified Genes 
Leber congenital amaurosis, autosomal dominant   1   1  
Leber congenital amaurosis, autosomal recessive   9   8  
Retinitis pigmentosa, autosomal dominant   17   17  
Retinitis pigmentosa, autosomal recessive   24   21  
Retinitis pigmentosa, X-linked   6   2  
Usher syndrome, autosomal recessive   11   9  
Bardet-Biedl syndrome, autosomal recessive   12   12  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Pattern of autosomal dominant RP inheritance. 
Approximately 20-30% of patients with RP have an 
associated non-ocular disease and would be classified as 
having syndromic RP. A list of non-syndromic and 
syndromic RP is maintained through RetNet 
(http://www.sph.uth.tmc.edu/retnet/). Table 2 shows the 
overall prevalence of non-syndromic or “simple” RP (not 
affecting other organs or tissues) and the proportion of the 
most common syndromic (affecting other systems such as 
hearing) or systemic (affecting multiple organs) RP. 
  The genetics of RP is complicated and clear genotype-
phenotype correlations are not yet possible. In addition to the 
multiplicity of mutations, in fact, (i) different mutations in 
the same gene may cause different diseases and (ii) the same 
mutation can exhibit intra- and inter-familial phenotypic 
variability (as for BEST1 mutations). For example, the vast 
majority of RHO mutations show a classical autosomal 
dominant inheritance leading to RP. Nevertheless, a few 
mutations show an autosomal recessive inheritance or lead to 
night blindness only [6]. Similarly, RPGR, the major X-
linked recessive RP gene, is associated with mutations in 
male patients and no male-to-male transmission of the 
phenotype has ever been observed. However, families with
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Fig. (2). Pattern of autosomal recessive RP inheritance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Pattern of X-linked RP inheritance. 
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daughters (who are therefore also carriers)Retinitis Pigmentosa  Current Genomics, 2011, Vol. 12, No. 4    241 
Table 2.  Estimated Percentages of RP Types 
Category Type  %   
Non-syndromic RP  Autosomal dominant RP  20-25 
  Autosomal recessive RP  15-20 
 X-Linked  RP  10-15 
 Leber  congenital  amaurosis  4 
  Digenic RP  Very rare 
Syndromic and systemic RP  Usher syndrome  10 
 Bardet-Biedl  syndrome  5 
Abbreviations: RP = Retinitis Pigmentosa. 
dominant inheritance pattern and female carriers showing 
disease symptoms of variable degree (likely due to the 
dominant nature of some of the mutations or non-random X-
inactivation in the affected tissue) have also been described 
[6]. Furthermore, mutations in some genes are associated 
with incomplete penetrance, thus making genotype-
phenotype correlations even more difficult. 
  In the next paragraphs we will overview the genes 
involved in the genesis of RP and how mutations can lead to 
patho-physiological consequences. A homogeneous and 
unique pattern of disease development cannot be envisaged 
as genes affected in RP are multiple and cover different steps 
of the visual cycle (phototransduction, retinal metabolism, 
tissue development and maintenance, cellular structure, 
splicing). For each of the main genes involved in RP, we will 
therefore evaluate the frequency of the mutations associated 
and how these lead to retinal degeneration and eventually 
RP. 
2. THE VISUAL CYCLE 
  In order to understand better how mutations in the genes 
involved in RP affect the activity of the proteins, a brief 
outline of the molecular bases of vision needs to be 
described. 
  Human vision begins when light enters the eye and is 
focused by the lens onto the photosensitive tissue at the back 
of the eye, the retina (Fig. (4)). Light-sensitive cells in the 
retina - the rod and cone photoreceptors – capture the 
incoming photons. The photoreceptors are polarized cells 
that consist of a synaptic region, a cell body, an inner 
segment (IS) and an outer segment (OS). The “molecular 
machinery” involved in biosynthesis, energy metabolism and 
membrane trafficking reside within the IS, which is 
connected to the OS via the so called connecting cilium. The 
OS is comprised of membranous discs surrounded by a 
plasma membrane. Over 90% of the total protein in the OS is 
rhodopsin, which resides both within the membrane of the 
discs and in the surrounding plasma membrane. Rhodopsin 
is one of the most extensively studied G-protein coupled 
receptors and its ligand-binding domain is buried within the 
transmembrane portion of the molecule. It is highly 
conserved among vertebrates and rhodopsin-like proteins can 
also be found in lower vertebrates. Vision in vertebrates 
begins with the absorption of light by the rod photoreceptor 
“visual pigment”, rhodopsin, which consists of an 
apoprotein, opsin (a single 384 amino acid polypeptide 
chain), and a chromophore (11-cis retinaldehyde, derived 
from vitamin A) attached to the opsin by a Schiff base bond. 
The absorption of light by rhodopsin causes isomerization of 
11-cis retinal to all-trans retinal, which changes opsin 
conformation, thus initiating vision. All-trans retinal is 
liberated from opsin in the photoreceptor cells and is reduced 
to  all-trans retinol, which moves to the retinal pigment 
epithelium (RPE). For vision to continue, 11-cis retinal has 
to be produced again from all-trans retinol in the RPE. This 
process is carried out by a 65kDa isomerohydrolase 
expressed in the RPE called RPE65 [7, 8]. The light-
activated rhodopsin interacts with and activates its cognate G 
(GTP-binding) protein, transducin, which subsequently 
initiates a canonical second-messenger signaling pathway via 
the heterotetrameric phosphodiesterase (PDE) 6 complex. 
3. NON-SYNDROMIC RETINITIS PIGMENTOSA 
3.1. Autosomal Dominant RP 
  To date mutations in 22 different genes are associated 
with autosomal dominant RP (adRP) (http://www.sph.uth. 
tmc.edu/retnet/; Fig. (1) and Table 3). However, only a few 
of these account for a relevant percentage of cases and 
include RHO (26,5%), PRPH2/RDS (5-9,5%), PRPF31 (8%) 
and RP1 (3,5%). 
Rhodopsin 
  As above described, rhodopsin (RHO) is the first 
component of the visual transduction pathway and is 
activated by absorption of light in the rod photoreceptor cells 
of the retina (reviewed in [10]). Mutations in the RHO gene 
account for 30 to 40% of all adRP, with more than 100 
different mutations (but Pro23His is found in approximately 
10% of Americans affected with adRP). The analysis of 
mutant rhodopsins suggests that mutations can impair 
protein folding, 11-cis retinal chromophore binding, G-
protein coupling/activation, and/or cellular trafficking of the 
rhodopsin protein. In addition, mutations in RHO can also 
lead to autosomal dominant congenital night blindness 
(CNB) and autosomal recessive retinitis pigmentosa (arRP). 242    Current Genomics, 2011, Vol. 12, No. 4  Ferrari et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Haematoxylin-stained section of the human retina (scale bar = 100μm). 
 
Table  3. Genes, Proteins and their Functions in Autosomal Dominant RP (Adapted from [6, 9] and 
http://www.sph.uth.tmc.edu/retnet/) 
Gene  Protein  % of all cases   Function Other  diseases/phenotypes 
BEST1  Bestrophin-1    Anion channel  Recessive RP 
CA4  Carbonic anhydrase IV  Arg14Trp 
found in 4% of 
Swedish 
controls 
Zn-containing enzyme that 
catalyzes hydration of carbon 
dioxide 
None 
CRX  Cone-rod homeobox protein  1,0  Transcription factor  Recessive and dominant LCA, 
dominant CORD 
FSCN2  Fascin homolog 2, actin-bundling protein    Cellular structure  None 
GUCA1B  Guanylate cyclase activator 1B    Phototransduction  Dominant MD 
IMPDH1  Inosine 5’-monophosphate dehydrogenase 
1 
2,5  Regulation of cell growth  Dominant LCA 
KLHL7 Kelch-like  7    Ubiquitin-proteasome protein 
degradation 
None 
NR2E3  Nuclear receptor subfamily 2, group E, 
member 3 
 Transcription  factor  Recessive RP; Recessive 
enhanced S-cone syndrome 
NRL  Neural retina leucine zipper protein    Tissue development and 
maintenance 
Autosomal recessive RP 
PRPF3  PRP3 pre-mRNA processing factor 3 
homolog (S cerevisiae) 
1,0 Splicing  None 
PRPF8  PRP8 pre-mRNA processing factor 8 
homolog (S cerevisiae) 
3,0 Splicing  None 
PRPF31  PRP31 pre-mRNA processing factor 31 
homolog (S cerevisiae) 
8,0 Splicing  None 
PRPH2 (RDS)  Peripherin 2  5-9,5  Photoreceptor outer segment 
structure 
Digenic forms with ROM1 
RDH12  Retinol dehydrogenase 12    Phototransduction  Recessive LCA 
 
 Ganglion Cell Layer
Inner Plexiform Layer
  Inner Nuclear Layer
Outer Plexiform Layer
Outer Nuclear Layer
     Rods and Cones
Pigmented EpitheliumRetinitis Pigmentosa  Current Genomics, 2011, Vol. 12, No. 4    243 
(Table 3). Contd….. 
Gene  Protein  % of all cases   Function Other  diseases/phenotypes 
RHO  Rhodopsin  26,5  Phototransduction  Recessive RP, dominant CSNB 
ROM1  Retinal outer segment membrane protein 1    Cellular structure  Digenic RP with PRPH2 (RDS) 
RP1  Retinitis pigmentosa 1  3,5  Tissue development and 
maintenance 
Recessive RP 
RP9  RP-9   Splicing None 
SEMA4A  Sema domain, immunoglobulin domain 
(Ig), transmembrane domain (TM) and 
short cytoplasmic domain (semiphorin) 4A 
  Tissue development and 
maintenance 
Dominant CORD 
SNRNP200  Small nuclear ribonucleoprotein 200kDa 
(U5) 
 Splicing  None 
TOPORS  Topoisomerase I binding, arginine/serine-
rich 
  localized in the basal body of 
connecting cilia in 
photoreceptors 
None 
Abbreviations: RP = Retinitis Pigmentosa; LCA = Leber congenital amaurosis; CSNB = congenital stationary night blindness; MD = macular dystrophy; CORD = cone-rod 
dystrophy. 
A documented case of arRP resulted from a mutation in the 
RHO gene that led to a protein that was missing the 6
th and 
7
th transmembrane domains, including the 11-cis retinal 
binding site [11]. Differently, RHO mutants associated with 
CNB appear to arise as a result of a constitutively active 
form of opsin that can catalytically activate the G-protein 
transducin in the absence of chromophore and in absence of 
light. Despite the amount of knowledge in adRP caused by 
mutations in RHO, therapeutic approaches have not 
proceeded at the same pace. Recently, visual function in 
P23H transgenic rats was restored following subretinal 
delivery of recombinant AAV vectors expressing the 
Bip/Grp78 gene (a chaperone protein able to promote 
trafficking of misfolded Pro23His rhodopsin to the cell 
membrane) [12]. Improved retinal function was also 
obtained in a mouse model of dominant RP following 
subretinal administration of recombinant AAV vectors 
carrying RNAi-based suppressors [13]. 
Pre-mRNA Processing Factor 31 (PRPF31) 
  PRPF31 was recently suggested to play a major role in 
adRP, with mutations ranging from 1 to 8% in adRP cohorts 
from various geographical origins (6,7% in a French adRP 
cohort) and higher frequencies in the United States [14]. 
PRPF31 is a pre-mRNA splicing factor of 61kDa, which is 
integral to the U4/U6+U5 trimer. To date over 40 mutations 
have been located in different parts of the gene and comprise 
missense substitutions, splice-site mutations, deletions and 
insertion. Interestingly, PRPF31 is one of three pre-mRNA 
splicing factors identified as causing adRP. Two other pre-
mRNA splicing factors have also been implicated in adRP: 
PRPF3 (RP18) found in 1% of cases and PRPF8 (RP13) 
found in 3% of cases (Table 3). Proteins encoded by these 
genes are essential for splicing in all cell types, yet the 
pathologic effects of mutations in all 3 genes is seen only in 
rod photoreceptors. Incomplete penetrance is one of the 
unique features associated with mutations in PRPF31.
 
Asymptomatic carriers can have affected parents and 
children,
 which can significantly complicate determining the 
mode of inheritance, thereby hindering the genetic 
counseling of the family. Previously, it has been reported 
that symptomatic individuals experience night blindness and 
loss of visual field in their teens and are typically registered 
as blind when they reach their 30s.
  Detailed haplotype 
analysis in PRPF31-linked families indicated that 
asymptomatic patients inherit a different wild-type allele 
from the one inherited by their symptomatic siblings, 
suggesting the existence of differentially expressed wild-type 
alleles that can potentially determine the penetrance of the 
disease symptoms. The high expression level of the wild-
type allele may compensate for the nonfunctional mutant 
allele, whereas the low-expressing wild-type allele is 
inadequate to reach the required photoreceptor-specific 
PRPF31 activity threshold [15, 16]. 
Peripherin 2 
  The peripherin 2 gene (PRPH2), formerly
 known as the 
retinal degeneration slow gene (RDS), consists
  of 3 exons 
and encodes a 39-kDa integral membrane glycoprotein
 with 
346 amino acids. The protein includes 4 transmembrane 
domains
 (M1-M4) and a large intradiscal domain (known as 
the D2 loop)
 and is located at the outer segment discs of the 
rod and cone
  photoreceptors. It forms a homo-oligomeric 
structure with
  itself and a mixture of homotetrameric and 
heterotetrameric
 complexes with another membrane protein 
(ROM1) [17]. This structure
  is important in disc 
morphogenesis and stabilization. Mutations
  in PRPH2 that 
cause RP were first described in 1991 and account for 5-
9,5% of adRP cases. Interestingly, cases of digenic RP have 
been observed following the simultaneous presence of a 
mutation in the PRPH2 (RDS) gene and a mutation in the 
ROM1 gene [18]. In all cases reported, the same PRPH2 
(RDS) mutation (L185P) was found, although three different 
ROM1 mutations were identified in these families. Studies 
carried out in Prph2Rd2/Rd2 mice have shown that the 
genetic defect can be corrected both morphologically and 
functionally by in vivo gene transfer. The ERGs of 
Prph2Rd2/Rd2 mice have greatly diminished a-wave and b-244    Current Genomics, 2011, Vol. 12, No. 4  Ferrari et al. 
wave amplitudes, which decline to virtually undetectable 
concentrations by two months. Subretinal injection of 
recombinant adeno-associated virus (AAV) encoding a 
Prph2 transgene resulted in stable generation of outer 
segment structures and formation of new stacks of discs 
containing both perpherin-2 and rhodopsin, which in many 
cases were morphologically similar to normal outer 
segments. Moreover, the re-establishment of the structural 
integrity of the photoreceptor layer also resulted in 
electrophysiological correction [19]. 
Retinitis Pigmentosa 1 
  The Retinitis Pigmentosa 1 (RP1) locus was originally 
mapped by linkage testing in a large adRP family in 
southeastern Kentucky and the RP1 gene subsequently 
identified by positional cloning. Mutations in RP1 cause 
both dominant and recessive forms of RP. Mutations in the 
RP1 gene account for approximately 5-10% of all adRP (4% 
in the United States) with the Arg677X mutation accounting 
for  of the total [from http://www.sph.uth.tmc.edu/retnet/]. 
The RP1 gene encodes a 240-kD retinal photoreceptor-
specific protein. RP1 is expressed prominently, if not only, 
in the photoreceptor cells of the retina and is involved in the 
correct orientation and higher order stacking of outer 
segment discs. RP1 is a microtubule-associated protein 
forming part of the photoreceptor axoneme and thus plays an 
important role in photoreceptor function [20, 21]. Clinical 
characterization of patients with RP1 disease shows notable 
differences in visual field diameters and ERG amplitudes in 
patients of the same age who share the same primary 
mutations.
 In general, variation in the phenotypes of genetic 
disorders can be attributed to allelic heterogeneity, 
environmental factors, and genetic modifiers.
  For  RP1 
disease, genetic modifiers are thought to be especially 
important because variation in the severity of disease is 
observed in patients with the same primary mutation and 
because environmental exposures are likely to be relatively 
similar within families. 
Diagnosis of adRP 
  As for the molecular diagnosis of adRP, an array has 
recently been developed and shown to enable the analysis of 
385 mutations in 16 different genes involved in adRP: CA4, 
FSCN2, IMPDH1, NRL, PRPF3, PRPF31, PRPF8, RDS, 
RHO, ROM1, RP1, RP9, CRX, TOPORS, and PNR 
(www.asperbio.com). 
3.2. Autosomal Recessive RP 
  Over 30 genes and loci (Table 4) have been implicated in 
autosomal recessive RP (Fig. (2)), even if most of them are 
rare, causing 1% or fewer cases. However, for some of them 
(RPE65, PDE6A, PDE6B and RP25) percentages can be 
higher, up to 2-5% of cases, and will therefore be more 
thoroughly described. 
Retinal Pigment Epithelium 65 
  Retinal pigment epithelium 65 (RPE65) is an 
isomerohydrolase expressed in retinal pigment epithelium 
and is critical for the regeneration of the visual pigment 
necessary for both rod and cone-mediated vision. More than 
60 different mutations have been found in the RPE65 gene, 
accounting for approximately 2% of recessive RP cases and 
16% of LCA patients. Several animal models, including the 
naturally occurring canine (Briard dog) and murine 
(Rpe65
rd12) models and the genetically engineered Rpe65-/- 
knockout mouse, have been widely used for pathological, 
biochemical, genetic, structural, functional and therapeutic 
studies (reviewed in [22]). Because of all these relevant 
models, for RPE65 mutations the mechanism leading to the 
disease is fairly well understood. The vitamin A derivative 
11-cis-retinal is the chromophore of rod and cone visual 
pigments. As previously described, absorption of light leads 
to an 11-cis to all-trans isomerization followed by 
dissociation of all-trans-retinal from the protein moiety 
(opsin) of the visual pigment holo-complex. Importantly, the 
crucial all-trans to 11-cis-retinoid isomerization reaction step 
takes place in the RPE and is catalyzed by RPE65. Rpe65-
deficient mice, in fact, lack 11-cis-retinal and consequently 
no rhodopsin is detectable in their eyes. Instead, these 
animals show an over-accumulation of retinyl esters, retinoid 
intermediates of the visual cycle, in the RPE [23]. 
  Results in pre-clinical studies have recently led to three 
encouraging gene therapy clinical trials in which patients 
affected by LCA were sub-retinal injected with recombinant 
adeno-associated viral vectors (rAAV) containing the human 
RPE65 cDNA [24-26]. Although the purpose of these initial 
studies was merely to test the safety of the gene transfer 
agent, all 3 groups did report modest (though significant) 
improvements in visual acuity. As a result of the 
groundbreaking positive reports, these three trials 
(NCT00516477, NCT00643747, NCT00481546, 
www.clinicaltrials.gov) are ongoing and expanding their 
patient population to examine treatment safety and efficacy 
further. 
PDE6A, PDE6B, PDE6G 
  Among the autosomal recessive RP genes so far 
identified, many encode proteins important in the rod 
photoreceptor visual transduction cascade. Central among 
these is the heterotetrameric phosphodiesterase (PDE) 6 
complex, consisting of ,  and two  subunits. The PDE6 
complex regulates the intracellular cGMP levels by 
hydrolyzing cGMP in response to light activation of G 
protein coupled receptors in cones and rods, thus making it 
an essential component of the visual phototransduction 
cascade [27]. In RP, mechanisms that initiate rod 
photoreceptor death are unclear; however, low levels of 
PDE6 activity are thought to lead to rod-cone degeneration. 
One hypothesis is that in PDE6 mutants an influx of calcium 
(Ca
2+) causes rod apoptosis, due to lack of PDE activation. 
Pharmaceutical interventions to block excessive Ca
2+ influx 
into rods have been attempted with variable success in 
mouse models (Pde6b
rd1/Pde6b
rd1mice) of the disease and 
Irish Setter dogs. Each subunit of the PDE6 complex is 
essential for photoreceptor function and maintenance, and, in 
fact, mutations within PDE6A (coding the phosphodiesterase 
6A) and PDE6B (coding the phosphodiesterase 6B) genes 
are the second most common identifiable cause of arRP 
(after mutations in the USH2A gene). About 36,000 cases of 
simplex and familial RP worldwide are due to defects in 
PDE6 complex, estimated to account for approximately 8% 
of all diagnosed arRP. In addition, mutations in the -subunit Retinitis Pigmentosa  Current Genomics, 2011, Vol. 12, No. 4    245 
Table  4. Genes, Proteins and their Functions in Autosomal Recessive RP (Adapted from [6, 9] and 
http://www.sph.uth.tmc.edu/retnet/) 
Gene Protein  % of all 
cases 
Function Other  diseases/phenotypes 
RP22 Unknown    Unknown  None 
RP29 Unknown    Unknown  None 
RP32 Unknown    Unknown  None 
ABCA4  ATP-binding cassette, subfamily A (ABC1), 
member 4 
2,9  Retinal metabolism  Recessive MD, recessive CORD 
BEST1  Bestrophin-1    Anion channel  Dominant RP 
C2ORF71  Chromosome 2 open reading frame 71    Unknown   
CERKL  Ceramide kinase-like protein    Tissue development and maintenance  None 
CNGA1  Cyclic nucleotide gated channel alpha1  2,3  Phototransduction  None 
CNGB1  Cyclic nucleotide gated channel beta1    Phototransduction  None 
CRB1  Crumbs homolog 1  6,5  Tissue development and maintenance  Recessive LCA 
EYS 
(RP25) 
Eyes shut homolog    Protein of the extracellular matrix  - 
FAM161A  Family with sequence similarity 161 member 
A 
  Unknown, localized in the 
photoreceptors 
- 
IDH3B  NAD(+)-specific isocitrate dehydrogenase 3 
beta 
  Involved in Krebs cycle   - 
IMPG2  Interphotoreceptor matrix proteoglycan 2    Component of the retinal intercellular 
matrix 
- 
LRAT  Lecithin retinol acyltransferase    Retinal metabolism  Recessive LCA 
MERTK  C-mer proto-oncogene tyrosine kinase    Transmembrane protein  None 
NR2E3  Nuclear receptor subfamily 2, group E, 
member 3 
 Transcription  factor  Dominant RP; Recessive 
enhanced S-cone syndrome 
NRL  Neural retina leucine zipper protein    Tissue development and maintenance  Dominant RP 
PDE6A  Phosphodiesterase 6A, cGMP-specific, rod 
alpha 
4,0 Phototransduction  None 
PDE6B  Phosphodiesterase 6B, cGMP-specific, rod 
beta 
4,0 Phototransduction  Dominant  CSNB 
PDE6G  Phosphodiesterase 6G, cGMP-specific, rod 
gamma 
 Phototransduction   
PRCD  Progressive rod-cone degeneration    Unknown function  - 
PROM1 Prominin  1    Cellular  structure  Recessive RP with macular 
degeneration 
RBP3  Retinol binding protein 3    Retinal metabolism  - 
RGR  Retinal G protein-coupled receptor    Retinal metabolism  Dominant choroidal sclerosis 
RHO Rhodopsin    Phototransduction Dominant  RP 
RLBP1  Retinaldehyde-binding protein 1    Retinal metabolism  Recessive Bothnia dystrophy 
RP1  RP-1 protein    Tissue development and maintenance  Dominant RP 
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(Table 4). Contd….. 
Gene Protein  % of all 
cases 
Function Other  diseases/phenotypes 
RPE65  Retinal pigment epithelium-specific 65kDa 
protein 
2,0  Retinal metabolism  Recessive LCA 
SAG  S-antigen; retina and pineal gland (arrestin)    Phototransduction  Recessive Oguchi disease 
SPATA7  Spermatogenesis associated protein 7    Unknown   
TTC8  Tetratricopeptide repeat domain 8    Cellular structure  Recessive Bardet-Biedl syndrome 
TULP1  Tubby-like protein 1    Tissue development and maintenance  Recessive LCA 
USH2A  Usher syndrome 2a  10,0  Cellular structure  Recessive Usher syndrome 
ZNF513  Zinc finger protein 513    Expression factor   
Abbreviations: RP = Retinitis Pigmentosa; LCA = Leber congenital amaurosis; CSNB = congenital stationary night blindness; MD = macular dystrophy; CORD = cone-rod 
dystrophy; cGMP = cyclic guanosine monophosphate. 
of PDE6B can lead to either progressive retinal disease, such 
as RP, or stationary disease, such as congenital stationary 
night blindness (CSNB). Heterozygous carriers of PDE6 
mutations are at a risk of losing vision when excessively 
inhibiting PDE6 with drugs such as sildenafil, tadalafil, or 
vardenafil [28]. More recently, a mutation (c187+1G>T) in 
the PDE6G gene encoding the gamma subunit of the rod 
cGMP phosphodiesterase was reported, thus confirming the 
involvement of PDE6G in autosomal-recessive early-onset 
RP [29]. 
RP25 
  Other mutations, while rare elsewhere, can be a common 
cause of arRP in specific populations, such as the RP25 
locus which was identified as the genetic cause of 10-20% of 
arRP cases in Spain [30]. 
Diagnosis of arRP 
  Tests available to screen mutations involved in arRP are 
so far well developed and able to detect up to 594 different 
mutations from several arRP-related genes including 
CERKL, CNGA1, CNGB1, MERTK, PDE6A, PDE6B, 
PNR, RDH12, RGR, RLBP1, SAG, TULP1, CRB, RPE65, 
USH2A, USH3A, LRAT, PROML1 and PBP3. In addition, 
many diagnostic laboratories offfer the possibility to have 
the entire coding region of the RPE65, PDE6 and USH2A 
genes sequenced. 
3.3. X-Linked RP  
  Around 10%-15% of RP patients have X-Linked RP 
(XLRP; Fig. (3)) and are characterized by a severe 
phenotype in the early stages of disease development. A 
milder phenotype can sometimes occur in female carriers, 
probably due to non-random or skewed inactivation of one X 
chromosome. In some patients, abnormal sperm 
development, impaired hearing and defects in the respiratory 
tract were observed, thus underlying the ciliary background 
of the disease (reviewed in [31]). 
  Six gene loci responsible for XLRP have been mapped 
on the X-chromosome (RP6, RP23, RP24, RP34, RP2 and 
RPGR – Table 5), but only two of these have been identified 
so far: the retinitis pigmentosa GTPase regulator (RPGR or 
RP3) and the retinitis pigmentosa 2 protein (RP2).  
 The  RPGR/RP3 gene product localizes in the outer 
segment of rod photoreceptors and is essential for their 
viability. Around 70% of XLRP patients have mutations in 
the  RPGR/RP3 gene. However, only 20% of the RP3 
Table 5.  Genes, Proteins and their Functions in X-Linked RP (Adapted from [6, 9] and http://www.sph.uth.tmc.edu/retnet/) 
Gene Protein  % of all 
cases 
Function Other  diseases/phenotypes 
RP2  Retinitis pigmentosa 2 protein  15,1  Human cofactor C is involved in 
beta-tubulin folding 
None 
RP6 Unknown    Unknown  None 
RP23 Unknown    Unknown  None 
RP24 Unknown    Unknown  None 
RP34 Unknown    Tissue development and 
maintenance 
None 
RPGR  Retinitis pigmentosa GTPase regulator  74,2  Intraflagellar transport  X-linked COD, X-linked CSNB 
Abbreviations: RP = Retinitis Pigmentosa; COD = cone dystrophy; CSNB = congenital stationary night blindness; GTPase = guanosine triphosphatase. Retinitis Pigmentosa  Current Genomics, 2011, Vol. 12, No. 4    247 
mutations occur within the exons coding for RPGR, while 
the ORF15 region turned out to be a mutational hotspot, with 
a mutation rate of 30-60% of all XLRP cases [32]. 
 The  predicted  RP2 gene product shows homology with 
human cofactor C, a protein involved in the ultimate step of 
beta-tubulin folding. Progressive retinal degeneration may 
therefore be due to the accumulation of incorrectly-folded 
photoreceptor or neuron-specific tubulin isoforms followed 
by progressive cell death. The gene responsible for RP2 was 
first cloned in 1998 and approximately 10-15% of XLRP 
patients have mutations in this gene. In contrast to RPGR, 
missense mutations and mutations leading to a truncated 
protein are distributed throughout the RP2 sequence 
(reviewed in [31]). 
  Differently from other forms, in X-linked RP, the two 
genes RPGR and RP2 alone account for more than 80% of 
the clinical cases and are therefore better target candidates 
for small-molecule drug or gene therapy approaches. As for 
the genetic analysis, a screening test able to evaluate up to 
184 mutations in RP2 and RPGR (excluding ORF15) genes 
is currently available (www.asperbio.com). 
4. SYNDROMIC RETINITIS PIGMENTOSA 
  In the majority of cases, RP is an isolated disorder 
(simple or non-syndromic), but there are also syndromic 
forms. In addition, infrequently, RP can also be found 
associated with other systemic conditions such as 
abetalipoproteinemia and Refsum disease. For the purpose of 
this review paper, we will only describe the more frequent of 
these syndromes, namely Usher syndrome and Bardet-Biedl 
syndrome. 
4.1. Usher Syndrome 
  Usher syndrome (USH) is an autosomal recessive disease 
characterized by the association of hearing loss, retinitis 
pigmentosa, and, in some cases, vestibular dysfunction. The 
syndrome is the most frequent cause of deaf-blindness, 
accounting for more than 50% of individuals who are both 
deaf and blind and affects between 1:12,000 – 1:30,000 
people in different populations. The Usher cases may 
represent between 10-30% of all autosomal recessive RP 
cases (reviewed in [33]). 
  Clinically, USH is divided into three types. Usher type I 
(USH1) is the most severe form and is characterized by 
severe to profound congenital deafness, vestibular areflexia, 
and pre-pubertal onset of progressive RP. Type II (USH2) 
displays moderate to severe hearing loss, absence of 
vestibular dysfunction, and later onset of retinal 
degeneration. Type III (USH3) shows progressive post-
lingual hearing loss, variable onset of RP, and variable 
vestibular response. 
  To date, five USH1 genes have been identified: MYO7A 
(USH1B), CDH23 (USH1D), PCDH15 (USH1F), 
USH1C(USH1C), and USH1G(USH1G). Three genes are 
involved in USH2, namely, USH2A (USH2A), GPR98 
(USH2C), and DFNB31 (USH2D). USH3 is rare except in 
certain populations (Finns and Ashkenazi Jews), and the 
gene responsible for this type is USH3A (Table 6).  
  Currently, there is no treatment available for USH. As for 
the diagnosis, an updated version of the Usher micro-array 
has recently been implemented by Asper Biotech (Tartu, 
Estonia) allowing to screen 612 mutations in the genes 
CDH23, MYO7A, PCDH15, Harmonin, SANS, USH2A, 
VLGR1, USH3A, and Whirlin. 
4.2. Bardet-Biedl Syndrome 
  Bardet-Biedl syndrome (BBS) is characterized by rod-
cone dystrophy (>90%), truncal obesity (72%), postaxial 
polydactyly, cognitive impairment, male hypogonadotrophic 
hypogonadism, complex female genitourinary 
malformations, and renal abnormalities. Renal disease is a 
major cause of morbidity and mortality. Birth weight is 
usually normal, but significant weight gain begins within the 
first year and becomes a lifelong issue for most individuals. 
  The visual prognosis for children with BBS is poor. 
Night blindness is usually evident by age seven to eight 
years and the mean age of legal blindness is 15.5 years. 
Atypical pigmentary retinal dystrophy with early macular 
involvement is the characteristic fundus abnormality in BBS 
[34, 35]. Visual acuity (central retinal function mediated by 
cones), dark adaptation, and peripheral visual fields 
(peripheral retina function mediated by rods) are all affected. 
  BBS is typically inherited in an autosomal recessive 
manner and affects 1 individual in 120,000 Caucasians. A 
higher incidence has been reported in isolated populations of 
Newfoundland (1 in 13000) [36] and among the Bedouins 
(ranging between 1:13500 and 1:6900 among the Bedouin 
population in the Jahra district) [37]. Fourteen genes are 
known to be associated with BBS: BBS1 (mutated in 40% of 
BSS families), BBS2  (mutated in 20% of BSS families), 
ARL6/BBS3, BBS4 (mutated in 3-6% of BSS families), BBS5 
(mutated in 2% of BSS families), MKKS/BBS6,  BBS7, 
TTC8/BBS8,  B1/BBS9,  BBS10,  TRIM32/BBS11, BBS12, 
MKS1/BBS13, and CEP290/BBS14  (from 
http://www.sph.uth.tmc.edu/retnet/). Molecular genetic 
testing is currently available on a clinical basis for all 14 
known BBS-related genes. However, approximately 20% of 
persons with BBS do not have identifiable mutations in any 
of the 14 genes and therefore, it is possible that more BBS-
related genes are yet to be identified. 
5. FUTURE DIRECTIONS 
  A reasonable hope is that in the near future, molecular 
testing of newly diagnosed patients with RP will be a routine 
part of clinical practice and will uncover the underlying 
disease-causing mutations in at least 95% of cases. However, 
for this hope to come true, the following conditions will need 
to be met: 
a.  Most of the genes causing RP must be identified. In 
spite of the large number of genes identified to date, 
the fraction of patients in which a mutation can be 
found by screening the known genes is often low; 
b.  It should be possible to detect nearly all of the 
disease-causing mutations within these genes; 
c.  Molecular testing should be inexpensive, reliable, fast 
and widely available; 248    Current Genomics, 2011, Vol. 12, No. 4  Ferrari et al. 
d.  Clinicians must be able to understand, interpret and 
explain the molecular information. 
  Several strategies do exist and novel technologies are 
emerging that increase the chance to identify the causative 
mutation in patients. Array-based diagnostic tests have 
nowadays been established for several retinal diseases, 
including RP; but allow to detect only known mutations. 
Next generation sequencing techniques, that is, novel gene 
selection and targeting methods followed by massively-
parallel, ultra-high-throughput sequencing, offer a rapid, 
efficient way to find disease-causing mutations in affected 
individuals and to discover new disease genes. These 
techniques have recently been applied to finding genes and 
mutations causing adRP in individuals/families in which 
conventional testing failed to detect mutations in known 
genes [38, 39]. 
  However, an important challenge for all these genetic 
tests is the interpretation of the results obtained. Many of the 
DNA sequence variations lead to amino acid substitutions 
and it is difficult to predict the pathogenic effects for many 
of them. Functional assays would therefore be needed to 
characterize these sequence alterations, but, due to the 
extensive individuality of pathogenic and non-pathogenic 
sequence alterations, this approach would be difficult to 
realize in a routine diagnostic setting. 
  What we really need today are comprehensive databases 
integrating genetic and clinical data in order to perform 
detailed genotype-phenotype comparisons. This would allow 
to reveal important information not only to diagnose RP in a 
patient or family for genetic counseling, but it may also have 
a predictive value with respect to the likelihood of disease 
development and choices of therapy (nutrition supplements, 
drugs, gene replacement strategies, stem cell technologies, 
etc.) [40]. 
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